Asia Markets Asia Markets - A different perspective

  • Latest
  • Stocks
  • Economy
  • Conflict
  • Inside China
  • Alternatives
  • People
  • Expert Insights
Asia Markets
  • Home
  • Aditya Raghunath

Author

Aditya Raghunath

Aditya is a senior correspondent with almost a decade of experience covering global equities.

He has provided stock analysis for well-known publications including Motley Fool, Yahoo Finance and Market Realist.

Stocks

Chinese ADRs: Boom or bust as the U.S. exodus continues?

Aditya Raghunath Aug 19, 2022
The U.S.-China accounting war is heating up with five state-owned Chinese enterprises announcing the voluntary delisting of their Chinese ADRs from American stock exchanges.
Economy

Indian stocks record best month this millennium – now what?

Aditya Raghunath Aug 12, 2022
Indian stocks have just enjoyed their best month in 23 years - and some analysts say momentum is only building.
Stocks

Alibaba investors await Thursday earnings release after brutal month

Aditya Raghunath Aug 3, 2022
The Alibaba stock price has ticked up ahead of the release of its Q2 earnings on Thursday morning. Here's the key things investors will be watching.
Stocks

What is Pinduoduo? Revolutionizing retail, generating profits

Aditya Raghunath Jul 5, 2022 0
Pinduoduo has been revolutionizing the Chinese retail landscape and making many investors a lot of money along the way. But outside of China, few know much about this rapidly growing e-commerce giant.
Stocks

Best China ETFs to consider right now (updated April 2022)

Aditya Raghunath Apr 19, 2022
Is now the right time to invest in China ETFs? Aditya Raghunath shares his top 4 ETF picks for April 2022.
Stocks

Indian tech stocks: Booming businesses to watch in 2022 and beyond

Aditya Raghunath Apr 10, 2022 0
India's tech sector is booming. So, Aditya Raghunath has outlined the case for four Indian tech stocks that should be on your radar for 2022 and beyond.
Stocks

BeiGene stock: Buy or sell China’s cancer-fighting Pharma giant?

Aditya Raghunath Mar 4, 2022
BeiGene is a commercial-stage biotechnology company specializing in developing cancer immunotherapies. While it has been capitalizing on strong structural tailwinds for medical research and development in recent years, there are many threats investors should…
Stocks

Baidu Hong Kong stock: Buy or sell? 

Aditya Raghunath Feb 22, 2022
Headquartered in Beijing, China, Baidu Inc. (NASDAQ: BIDU, HK: 9888) is the largest search engine provider in the country and one of the biggest tech conglomerates globally.
Stocks

Ping An stock: Should you invest in 2022?

Aditya Raghunath Feb 15, 2022
Ping An Insurance is one of the world’s largest insurance and tech-powered retail financial services companies. Aditya Raghunath considers if now is the time to buy Ping An stock.
Stocks

Why the Sinopec stock price finally looks poised for outperformance

Aditya Raghunath Feb 9, 2022
Due to a subdued pricing environment in the past decade, shares of Sinopec have gained just 7.5% since January 2012, but is that about to change?
Older Posts

MOST READ

Stocks

Chinese banks cause alarm as capital flight measures intensify

Mar 5, 2023
Stocks

Suspicious Silicon Valley Bank options trade generated $1.2m…

Mar 10, 2023
Stocks

Who is Larry McDonald? And why he thinks the stock market will…

Mar 9, 2023
Stocks

Who owns SVB bonds? The 5 biggest SVB bondholders revealed

Mar 13, 2023
Meme Stocks

Troika Media Group stock becomes latest short squeeze phenomenon

Mar 7, 2023
Economy

Housing market crash: U.S. facing “rapidly evolving…

Feb 26, 2023
Stocks

Silicon Valley Bank CEO Greg Becker sold SIVB stock in January,…

Mar 10, 2023
Stocks

Russia aircraft carrier tow creates speculation about…

Mar 8, 2023
Loading ... Load More Posts No More Posts
asiamarkets.com
  • Stocks
  • Economy
  • Conflict
  • Inside China
  • Meme Stocks
  • Alternatives
  • Expert Insights
  • Guides
  • Subscribe
  • About
  • Advertise
  • Privacy Policy
© 2023 - Asia Markets. All Rights Reserved.
  • Latest
  • Stocks
  • Economy
  • Conflict
  • Inside China
  • Alternatives
  • People
  • Expert Insights